<DOC>
	<DOCNO>NCT00441116</DOCNO>
	<brief_summary>The aim Phase III study compare efficacy , safety tolerability dutasteride ( 0.5mg ) placebo 6 month , Korean male subject androgenetic alopecia vertex region , type IIIv , IV V accord modify Norwood-Hamilton Classification .</brief_summary>
	<brief_title>A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Inclusion criterion : Rationale The vertex area scalp evaluate study , therefore inclusion criterion Norwood Hamilton area IIIv , IV V ensure subject vertex hair loss recruit line primary efficacy endpoint change hair growth vertex . A subject eligible inclusion study follow criterion apply : 1 . Male outpatient age 1849 year , inclusive 2 . Diagnosis Male Pattern Hair Loss classify type IIIv , IV , V utilise modify NorwoodHamilton classification ( Figure 1 ) ( N.B . type IVa Va exclude ) 3 . Able comprehend instruction record require information 4 . Will provide sign dated write informed consent participate investigation Exclusion criterion : A subject eligible inclusion study follow criterion apply : 1 . Evidence hypogonadism define serum testosterone &lt; 250ng/dl and/or LH &gt; 20mIU/ml Note : If initial serum testosterone result &lt; 250ng/dl LH value normal , test may repeat . Attempts make , possible , collect sample morning hour . If repeat testosterone result &lt; 250ng/dl , subject eligible participation . 2 . Greater two time upper limit normal ALT AST , bilirubin great 2.0mg/dl ( exception subject diagnose Gilbert 's syndrome eligible participate study ) 3 . Serum creatinine &gt; 1.8mg/dl 4 . Global scalp hair thin , include occipital area 5 . Scarring scalp condition disease scalp hair , include disease hair shaft ( e.g. , uncontrolled seborrheic dermatitis , tinea infection , cause alopecia , prior hair transplant scalp reduction , psoriatic dermatitis ) inability discontinue use hair weave . 6 . Subjects use hair colourants/hair dye , remain trace colourants hair . Subjects must maintain natural hair colour throughout study . 7 . Hair length nonbalding area â‰¤2cm ( 3/4 inch ) around vertex region head . Subjects must maintain hairstyle throughout study . 8 . History malignancy within past five year , except basal cell squamous cell carcinoma skin 9 . Serum PSA level &gt; 2.0 ng/ml screen visit . 10 . Family history ( Father , brother ) prostate cancer . 11 . Active unstable thyroid disease , include subject therapy either hyperthyroidism hypothyroidism unless dose thyroid medication stable 3 month serum TSH normal 12 . Hypersensitivity 5 AR inhibitor drug chemically relate study medication 13 . Use finasteride 5 AR inhibitor within 12 month prior screen . 14 . Previous use dutasteride . 15 . Use phytotherapy ( e.g . saw palmetto ) within 8 week prior screen . 16 . Previous use cytotoxic agent 17 . Use glucocorticoid ( inhaled glucocorticoid allow ; topical steroid allow provide used scalp ) within 3 month prior screen 18 . Use follow 6 month prior screen : Minoxidil ( oral topical ) Drugs antiandrogenic property ( e.g. , cyproterone acetate , spironolactone , ketoconazole , flutamide , bicalutamide ) . Cimetidine use study exclude drug use previous 6 month . Topical estrogen , progesterone Tamoxifen Drugs potentially cause hypertrichosis ( e.g. , cyclosporine , diazoxide , phenytoin psoralens ) Anabolic steroids Lithium phenothiazine 17 . Concurrent regular use 4 week prior screen topical agent scalp ( e.g. , antiinflammatories ) 18 . Participation investigational market drug trial within 30 day precede screen phase study . Participation drug trial course study include followup period . 19 . History current evidence drug alcohol abuse within 12 month prior screen 20 . History illness ( include psychiatric ) may impair ability provide inform consent comply study requirement 21 . History unstable illness condition , opinion investigator , might confound result put subject risk . 22 . Subjects know HIV positive ( status include subject AIDS ) 23 . Subjects refrain donate blood complete study followup period .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>dutasteride</keyword>
	<keyword>Androgenic alopecia</keyword>
	<keyword>phase 3</keyword>
</DOC>